enow.com Web Search

  1. Ads

    related to: list of approved complement inhibitors for diabetes treatment

Search results

  1. Results from the WOW.Com Content Network
  2. SGLT2 inhibitor - Wikipedia

    en.wikipedia.org/wiki/SGLT2_inhibitor

    SGLT2 inhibitors are used in the treatment of type 2 diabetes. Apart from blood sugar control, gliflozins have been shown to provide significant cardiovascular benefit in people with type 2 diabetes. [2] [3] As of 2014, several medications of this class had been approved or were under development. [4]

  3. List of therapeutic monoclonal antibodies - Wikipedia

    en.wikipedia.org/wiki/List_of_therapeutic...

    This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.

  4. Discovery and development of gliflozins - Wikipedia

    en.wikipedia.org/wiki/Discovery_and_development...

    Gliflozins are a class of drugs in the treatment of type 2 diabetes (T2D). They act by inhibiting sodium/glucose cotransporter 2 (SGLT-2), and are therefore also called SGLT-2 inhibitors. The efficacy of the drug is dependent on renal excretion and prevents glucose from going into blood circulation by promoting glucosuria .

  5. Sodium/glucose cotransporter 2 - Wikipedia

    en.wikipedia.org/wiki/Sodium/glucose_cotransporter_2

    SGLT2 inhibitors are also called gliflozins or flozins. They lead to a reduction in blood glucose levels, and therefore have potential use in the treatment of type 2 diabetes. Gliflozins enhance glycemic control as well as reduce body weight and systolic and diastolic blood pressure. [9]

  6. Ravulizumab - Wikipedia

    en.wikipedia.org/wiki/Ravulizumab

    Ravulizumab, sold under the brand name Ultomiris, is a humanized monoclonal antibody complement inhibitor medication designed for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome. It is designed to bind to and prevent the activation of Complement component 5 (C5). [8] [7]

  7. Diabetes medication - Wikipedia

    en.wikipedia.org/wiki/Diabetes_medication

    Exenatide (also Exendin-4, marketed as Byetta) is the first GLP-1 agonist approved for the treatment of type 2 diabetes. Exenatide is not an analogue of GLP but rather a GLP agonist. [32] [33] Exenatide has only 53% homology with GLP, which increases its resistance to degradation by DPP-4 and extends its half-life. [34]

  1. Ads

    related to: list of approved complement inhibitors for diabetes treatment